Skip to main content
US EQUITIES CLOSED CRYPTO 24/7
HALAL TRADING ROOM Sharia-screened signals
TERMINAL
PB

PBHStockPrestige Consumer Healthcare Inc.

New York Stock Exchange · Healthcare

$43.67 last close 2026-11-09
Open in terminalCompare
Price alert

Verdicts genuinely change. Free email alert the moment PBH's does — no target price to set, unlike a price alert.

Sharia status
NOT YET SCREENED
Not screened yet — no methodology has been established for this symbol
HTR non-permissible income 0.03%

Methodology breakdown computing — it will appear here on its own.

🕌Open research, not a fatwa — verify with your own scholar.

Trade setup

Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.

SEPARATE FROM SHARIAH
No active setup right now. The technical picture doesn't show a clear edge — check back when the trend or momentum shifts.

Why this signal?

The factors behind the read, each shown with the figure it rests on, including the ones pointing the other way.

Structure2 of 5 timeframes bullish · 60.9% aligned
VWAPPrice below VWAP ($46.07)
VolumeRelative volume 6.2× the 20-day average
Momentum10-day rate of change -9.3%
Market & analysts
Wall Street consensus
BUY
10 analysts
Price target
$66.20
+51.6% · 5 analysts
Institutional own.
115.1% *
of shares
Momentum (10d)
-9.3%
rate of change
SMC grade
C · 62
60.9% aligned
100.00% *
Purification ratio (secondary provider, uncertain)
0.03%
Non-permissible income — HTR, from filings (2026-03-31)
C · 62
SMC grade — 60.9% timeframe alignment
-9.3%
Rate of change (10d)
BUY
Wall Street consensus (10)
$66.20
Price target (+51.6%) · 5 analysts
115.1%
Institutional ownership *

🕌 In-house Compliance Research

Computing the full ratio and business-activity breakdown for PBH — this runs off the critical path so the page paints first. It will appear here on its own.

Tracked investors holding PBH
InvestorFirmPositionWeightAs of
Ken Fisher Fisher Asset Management $12M 0.0% 2026-06-30
Ray Dalio Bridgewater Associates $2M 0.0% 2026-06-30
Azzad Asset Management Azzad Asset Management $1M 0.1% 2026-06-30

From the most recent 13F on file. A 13F reports long US equity positions quarterly and in arrears — it is what a manager held on the report date, not what they hold today.

70.2163.4056.5949.7942.982025-11-102026-05-122026-11-09

Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset

Support & Resistance
S3
40.11
S2
40.94
S1
41.96
PIVOT
42.79
R1
43.81
R2
44.64
R3
45.66

Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.

Price Forecast

The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.

7-day expected range
42.12 – 51.10
±9.63% from 46.61, made 2026-09-26 · resolves 2026-10-03
STRONG SELL
from 19 indicators
61.9% of our last 5789 forecasts — across every instrument we forecast, not just this one — landed inside their stated range, and 49.9% called the direction correctly.

Technical Summary

Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.

STRONG SELL
19 indicators
OscillatorsNEUTRAL
3 buy · 1 neutral · 3 sell
Moving averagesSTRONG SELL
0 buy · 0 neutral · 12 sell
Every indicator, and what it reads
IndicatorValueSignal
RSI (14)38.90NEUTRAL
Stochastic %K (14)16.34BUY
CCI (20)-224.72BUY
Williams %R (14)-83.66BUY
MACD (12,26,9)-0.58SELL
ROC (10)-9.30SELL
Momentum (10)-4.48SELL
EMA (10)46.92SELL
SMA (10)47.65SELL
EMA (20)47.59SELL
SMA (20)48.25SELL
EMA (30)47.83SELL
SMA (30)47.74SELL
EMA (50)48.23SELL
SMA (50)47.99SELL
EMA (100)49.49SELL
SMA (100)49.07SELL
EMA (200)53.42SELL
SMA (200)53.53SELL

About Prestige Consumer Healthcare Inc.

Healthcare · Drug Manufacturers - Specialty & Generic

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. It operates in two segments, North American OTC Healthcare and International OTC Healthcare. The company offers analgesic powders under the BC and Goody's brand; various diaper rash treatments and skin protectants for babies under the Boudreaux's Butt Paste brand name; sprays and lozenges to relieve sore throats and mouth pain under the Chloraseptic brand; eye care products that provide relief from redness and itchiness under the Clear Eyes brand name; at-home removal of common and plantar warts under the Compound W brand; and ear wax removal products under the Debrox brand name. It also provides dental guards, floss picks, interdental brushes, dental repair and kits, and tongue cleaners under the DenTek brand; motion sickness relief products under the Dramamine brand; enemas and other laxative products under the Fleet brand name; stomach upset remedies under the Gaviscon brand; cough drops under the Luden's brand; products for yeast infections in women under the Monistat brand name; lice and parasite treatments under the Nix name; feminine care products, including washes, cloths, and sprays under the Summer's Eve brand; products for dry eyes under the TheraTears brand; nasal saline sprays and washes under the Fess brand name; and oral rehydration products under the Hydralyte brand. It sells its products to mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.

prestigebrands.com ↗

Background via Yahoo Finance — informational, not part of the verdict.

Grade verdict

Average — needs more confirmation before sizing up

SMC — Top Down

Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.

TimeframeBiasBars
📅 Daily BEARISH 42
⏰ 4H RANGING 34
🕐 1H BEARISH 98
⏱ 15-Min BULLISH 130
⏲ 5-Min BULLISH 234

Momentum & Volume

Rate of change and relative volume against this symbol's own recent history. Momentum describes what price has done; it is not a claim about what it will do.

-9.3%
Rate of change (10d)
6.2×
Volume vs its 20-day average
-0.31
MACD (no fresh cross)

Peer Movement

How the rest of the sector moved over the same window. Context for a price move, never a cause of one.

Peer movement computing — it will appear here on its own.

Before you act on this

The questions worth asking about any verdict on this page, answered plainly.

Is this a fatwa?

No. HTR applies published screening standards to a company's own filings and shows the result under each one. It is research, not a religious ruling. For a ruling that applies to you, ask a qualified scholar.

Why can the standards disagree?

Because they measure different things. Some divide interest-bearing debt by market cap, others by total assets, and the thresholds differ too. The same filing can clear one line and cross another. HTR shows every verdict rather than averaging them into one label.

How often is this re-screened?

Ratios are recomputed when a new filing lands, and the whole watchlist is re-screened on a rolling basis. The date on the verdict above is the last time this symbol was actually recomputed, not the last time the page was built.

Do I need to purify dividends?

If a company earns some non-permissible income, many scholars hold that the same share of any dividend should be given away. The non-permissible income figure above is the number that calculation starts from — the purification calculator finishes it, showing the filing figures behind the ratio and both the proportional and the AAOIFI per-share convention.

Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.

Compare with

Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.

Peer screening computing — it will appear here on its own.

Insider Activity (90d)

Insider transactions reported in the last ninety days. Insiders sell for reasons that have nothing to do with a view, so a sale on its own is not a signal.

NO DATA   0 buys · 0 sells

COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE

The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.

NEUTRAL   report date 2026-11-03 · Asset managers net 928584 (+5135)

AI Summary

Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.